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Background. Despite extensive research and an improved standard of care, sepsis remains a disorder with a high mortality rate.
Sepsis is accompanied by severe metabolic alterations. Methods. We evaluated 117 patients with sepsis (severe sepsis [𝑛 = 19] and
septic shock [𝑛 = 98]) who were admitted to the intensive care unit. Serum cholesterol, triglyceride (TG), high-density lipoprotein
(HDL), low-density lipoprotein (LDL), free fatty acid (FFA), and apolipoprotein (Apo) A-I levels were measured on days 0, 1, 3,
and 7. Results. Nonsurvivors had low levels of cholesterol, TG, HDL, LDL, and Apo A-I on days 0, 1, 3, and 7. In a linear mixed
model analysis, the variations in TG, LDL, FFA, and Apo A-I levels over time differed significantly between the groups (𝑝 = 0.043,
𝑝 = 0.020, 𝑝 = 0.005, and 𝑝 = 0.015, resp.). According to multivariate analysis, TG levels and SOFA scores were associated with
mortality on days 0 and 1 (𝑝 = 0.018 and 𝑝 = 0.008, resp.). Conclusions. Our study illustrated that TG levels are associated with
mortality in patients with sepsis. This may be attributable to alterations in serum lipid metabolism during sepsis, thus modulating
the host response to inflammation in critically ill patients.
1. Introduction
Although mortality caused by severe sepsis with or without
shock decreased between 2000 and 2012, it remains a leading
cause of inhospital death [1]. There is no proven targeted
therapy for severe sepsis, despite intensive research and ran-
domized controlled trials. The total hospital costs associated
with sepsis syndrome are increasing annually [2]. Further-
more, the incidence of sepsis has increased worldwide [3].
Lipopolysaccharide (LPS), the major component of the
outer membrane of Gram-negative bacteria, plays a key role
in the initiation of sepsis. After LPS binds toCD14, the inflam-
matory cascade begins [4, 5]. In addition, there is a signifi-
cant transition in the distribution of circulating lipoproteins
before and after sepsis [6]. Previous studies illustrated that
lipoprotein plays an important role in LPS binding and neu-
tralization, enzyme incorporation, including paraoxonase
and platelet-activating factor acetylhydrolase, inhibition of
the expression of endothelial cell adhesion, and stimulation
of the expression of endothelial nitric oxide synthase in vitro
[7, 8].
Cholesterol and lipoprotein levels change rapidly over
time in patients with proinflammatory conditions, especially
in critically ill intensive care unit (ICU) patients with severe
infection or sepsis [8, 9]. Patients with severe sepsis have
low levels of cholesterol, including high-density lipoprotein
(HDL), low-density lipoprotein (LDL), and apolipoprotein
A-I (Apo A-I) and high levels of triglycerides (TGs) and free
fatty acids (FFAs) [9, 10].
Although lipid changes over time have been studied
previously, only HDL has been studied extensively. There
are only a few studies examining changes in serum lipid
levels other than HDL over time in patients with sepsis, and
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Figure 1: Flow chart of the inclusion and exclusion of patients in the study. A total of 179 patients were enrolled betweenAugust andDecember
2008, and 117 patients were included in the analysis. Patients who were being admitted for a second time (𝑛 = 4), those using steroids (𝑛 = 26),
and those with a history of dyslipidemia (𝑛 = 13) or liver disease (𝑛 = 22) were excluded. Note: one patient had dyslipidemia and liver disease
and two patients had liver disease and used steroids (≥15mg/day) within the previous 7 days.
the prognostic implications of changes in lipoprotein content
remain unclear. Furthermore, most of these studies of lipid
profiles were conducted in Western populations. Recently,
simvastatin and rosuvastatin failed to provide better clinical
outcomes in patients with acute respiratory distress syn-
drome (ARDS) or sepsis-associated ARDS [11, 12]. As a result,
there are controversies related to the concentration of lipids
[4, 13, 14], and further studies with Asian patients are needed
because of ethnic differences, namely, low body mass indices
(BMIs) and low-fat diets. To the best of our knowledge, no
prior studies examined lipid profiles and sepsis using multi-
variate and survival analyses.The purpose of this study was to
examine the difference and dynamic changes in serum lipid
levels, including Apo A-I, in ICU patients with sepsis and
evaluate whether these lipids are associated with prognosis.
2. Methods
2.1. Study Subjects. This was a prospective blood sampling
and retrospective data analysis of a cohort of patients admit-
ted to the medical ICU at a 2500-bed tertiary university
medical center in Seoul, South Korea. The medical ICU
is a 30-bed closed unit that is managed by certified ICU
care specialists who only care for ICU patients. We enrolled
patients admitted to the ICUwith sepsis between August and
December 2008; a total of 179 ICU patients were enrolled.
Patients were excluded if they met specific criteria: age less
than 18 years, pregnancy, ICU readmission, and a need for
primary cardiac care. Patients with liver disease (hepatitis B,
hepatitis C, immune hepatitis, liver cirrhosis, and hepato-
cellular carcinoma), dyslipidemia, or a history of statin or
steroid (≥15mg/day) use within the previous 7 days were also
excluded from the study. Similarly, patients who had been
treated with corticosteroid therapy for septic shock prior to
admission to ICU were excluded. Finally, 117 patients were
included for analysis in this study (Figure 1).
Sepsis was clinically defined as the identification of
an infection site and three or four systemic inflammatory
response syndrome (SIRS) criteria: (1) body temperature
less than 36∘C (96.8∘F) or greater than 38∘C (100.4∘F); (2)
heart rate greater than 90 beats/min; (3) tachypnea of greater
than 20 breaths/min or an arterial partial pressure of carbon
dioxide less than 4.3 kPa (32mmHg); and (4) white blood cell
count of less than 4000 cells/mm3 (4 × 109 cells/L) or greater
than 12,000 cells/mm3 (12 × 109 cells/L) [15]. Septic shock
was defined as the state of sepsis with persistent hypotension
despite adequate volume resuscitation [16, 17]. All eligible
patients in this study were managed according to “Surviving
sepsis campaign: international guidelines for management of
severe sepsis and septic shock: 2008” [18]. Once admitted to
the ICU, patients were evaluated by a specialized nutrition
team, who estimated the nutrition status of each patient
and evaluated the possibility of enteral feeding. In total, 66
patients (56.4%)were supported by total parenteral nutrition,
and 51 patients (43.6%) were supported by enteral feeding.
Each patient was supplied with 20–30 kcal/kg/day of nutri-
tion, depending on the patient’s nutrition status, according
to the guidelines of the American Society for Parenteral
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and Enteral Nutrition or the European Society for Clinical
Nutrition and Metabolism [19, 20]. Additionally, patients
were treated using an insulin protocol, targeting a level
of 100–140mg/dL, which we developed on the basis of a
modification of the Yale protocol [21]. Propofol, which affects
lipid profiles, was not used in this study.
For each patient, data on age, gender, BMI, comorbidity,
infection strain, administration of vasoactive drugs, length
of ICU stay, and 28-day mortality were collected. In addi-
tion, Acute Physiology and Chronic Health Evaluation II
(APACHE II) scores, Sequential Organ Failure Assessment
(SOFA) scores, and laboratory data, including cholesterol,
TG, HDL, LDL, FFA, and Apo A-I serum levels, were col-
lected on days 0 (ICU admission), 1, 3, and 7.
2.2. Blood Sampling and Assays. Blood samples were
obtained using an indwelling arterial catheter or via venous
puncture as soon as possible after the patient was admitted to
the ICU. Blood samples from days 1, 3, and 7 were obtained at
a fixed time (5 AM) for all eligible patients. The levels of total
cholesterol (normal range: 100–220mg/dL), HDL (normal
range: 40–86mg/dL), TG (normal range: 44–240mg/dL),
LDL (normal range: 70–169mg/dL), and FFA (normal range:
150–600 𝜇Eq/L) were measured using commercial kits with
an automated analyzer (Hitachi 7600-200-DDP, Hitachi Ltd.,
Tokyo, Japan). Apo A-I (normal range: 0.0–25.0mg/dL) was
measured using an autoanalyzer (Hitachi 7600-210 P-modu-
lator, Hitachi Ltd.).
2.3. Statistical Analysis. Continuous variableswere compared
using Student’s t-test or Mann-Whitney’s 𝑈 test, depending
on the distribution, and were presented as the mean ± stan-
dard deviation or median (interquartile range). Categorical
variables were compared using Pearson’s chi-squared test or
Fisher’s exact test and were presented as absolute frequencies
and percentages. The changes in serum levels in the lipid
profile over time were compared between the groups using
linear mixed model analysis after adjusting for age, sex, and
BMI.The effect of age, gender, BMI, SOFA scores, and serum
lipid levels on survival was evaluated using Cox proportional
hazardmodels. Pearson’s correlation was performed to inves-
tigate the association between lipid levels and SOFA scores.
Thepredictive receiver operating characteristic (ROC) curves
of 28-day mortality were compared between the SOFA score
and SOFA score/TG level.The effects of TG levels on survival
were assessed using Cox proportional hazards models. An
adjusted𝑝 value<0.05was considered statistically significant.
All statistical analyses were performed using SPSS version 20
(SPSS, Chicago, IL, USA).
2.4. Ethics Statement. The study protocol was reviewed and
approved by the Institutional Review Board (IRB) of Yonsei
University Health Service, Severance Hospital (IRB approval
number 4-2008-0099). Informed consent was obtained from
patients or their next of kin.
3. Results
The baseline demographic and clinical characteristics of the
study subjects (𝑛 = 117) at admission to the ICU (day 0)
are shown in Table 1. The mean age of the 117 patients was
62.7±16.2 years. Age, gender, and BMI were similar between
the survivor and nonsurvivor groups. SOFA and APACHE II
scores were elevated in the nonsurvivor group (𝑝 = 0.008 and
𝑝 = 0.082, resp.).The lungswere themost commonly infected
sites (80.3%). There were no significant differences between
the two groups with respect to comorbidities. In addition, no
significant differences were observed for clinical parameters.
C-reactive protein (CRP) levels were elevated in the nonsur-
vivor group, albeit not significantly compared to the survivor
group. Albumin levels were also not significantly different
between the two groups. However, TG and FFA levels were
significantly higher in the survivor group than in the non-
survivor group. The levels of other lipoproteins (cholesterol,
HDL, LDL, and Apo A-I) were also increased in the survivor
group; however, the differences between the groups were not
statistically significant.
The changes in serum lipid levels over time are shown in
Figure 2. Serum lipid and lipoprotein levels were investigated
from the day of admission to the ICU (day 0) to day 7.
Changes in TG, LDL, FFA, and Apo A-I levels over time
differed significantly between the two groups (𝑝 = 0.043,
𝑝 = 0.010, 𝑝 = 0.005, and 𝑝 = 0.006, resp.). However,
changes in cholesterol andHDL levels over time did not differ
significantly between the two groups. At different time points,
there was a significant gap in the mean value for each lipid
and lipoprotein between the two groups. Cholesterol levels
were significantly elevated in the survivor group ondays 3 and
7 compared to those of the nonsurvivor group. In addition,
TG content was significantly elevated in the survivor group
on days 0 and 1. Furthermore, significant differences were
observed for HDL on day 3, LDL on day 7, FFA on day 0, and
Apo A-I on day 7.
Using a Cox proportion hazard model, we performed
survival analysis for each lipid level after adjusting for age,
gender, BMI, and SOFA score on days 0, 1, 3, and 7 (Table 2).
A total of 24Coxproportionhazardmodelswere constructed.
On days 0 and 1, TG levels were significantly associated with
survival. The hazard ratio (HR) decreased with TG levels
(𝑝 = 0.015, HR = 0.991, and 95% confidence interval [CI] =
0.984–0.998 on day 0; 𝑝 = 0.002, HR = 0.988, and 95% CI =
0.980–0.995 on day 1). Elevated LDL content on day 1 was
associated with poor prognosis (𝑝 = 0.047, HR = 1.015, and
95% CI = 1.000–1.030). There was no significant association
between the other lipids and survival.
The correlation between serum lipid levels and SOFA
scores is shown in Table 3. Overall, the level of each lipid
correlated well with the SOFA score, excluding TG and FFA.
TG levels were not correlated with SOFA scores for the 7 days
of ICU stay. The continuous TG level/SOFA score curve is
shown in Figure 3, and it was a more accurate predictor of
the 28-day mortality rate in ICU patients with sepsis than
the SOFA score alone (area under the curve [AUC] = 0.717,
𝑝 < 0.001 and AUC = 0.634, 𝑝 = 0.029, resp.).
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Table 1: Baseline characteristics of patients at ICU admission (𝑛 = 117, day 0).
Variables Survivors Nonsurvivors 𝑝 value
(𝑛 = 65) (𝑛 = 52)
Age, yr 63.0 ± 16.6 62.3 ± 15.9 0.832
Male (%) 42 (64.6) 31 (59.6) 0.579
BMI, kg/m2 22.6 ± 4.1 22.9 ± 3.8 0.754
Length of ICU stay, days∗ 11.0 [5, 20.5] 12.5 [3.3, 23.8] 0.695
Severe sepsis 17 (26.2) 2 (3.8) 0.001
Septic shock 48 (73.8) 50 (96.2) 0.001
APACHE II score 18.3 ± 6.0 20.0 ± 5.0 0.082
SOFA score 6.9 ± 3.1 8.6 ± 3.7 0.008
Infection site 0.014
Lung 45 (69.2) 49 (94.2)
Urinary tract 5 (7.7) —
Abdomen 11 (16.9) 3 (5.8)
Others∗ 4 (6.1) —
Underlying diseases
Diabetes mellitus 21 (32.3) 9 (17.3) 0.065
Chronic lung disease† 10 (15.4) 14 (26.9) 0.125
Chronic renal disease 11 (16.9) 9 (17.3) 0.956
Hypertension 27 (41.5) 19 (36.5) 0.582
Heart failure 9 (13.8) 6 (11.5) 0.711
Coronary artery disease 6 (9.2) 6 (11.5) 0.683
Chronic liver disease 4 (6.2) 6 (11.5) 0.301
Clinical parameters
Hemoglobin, g/dL 10.2 ± 2.2 9.6 ± 2.1 0.151
Platelets, 103/mm3 204.9 ± 157.7 177.6 ± 145.6 0.338
Albumin, g/dL 2.7 ± 0.7 2.6 ± 0.6 0.185
Blood urea nitrogen, mg/dL 32.3 ± 27.2 30.9 ± 25.2 0.776
Creatine, mg/dL 2.1 ± 2.1 1.7 ± 1.8 0.224
CRP, mg/dL 15.2 ± 11.1 19.6 ± 14.0 0.068
Lipids∗
Cholesterol, mg/dL 106.0 [78.0, 132.0] 84.5 [57.5, 129.5] 0.196
Triglyceride, mg/dL 100.0 [66.5, 188.5] 81.0 [61.8, 113.5] 0.011
High-density lipoprotein, mg/dL 21.0 [13.0, 30.5] 21.0 [9.0, 27.0] 0.411
Low-density lipoprotein, mg/dL 46.0 [29.5, 69.5] 39.0 [22.0, 65.0] 0.414
Free fatty acid, 𝜇Eq/L 487.5 [287.0, 742.8] 441.0 [222.0, 570.8] 0.026
Lipoprotein A, mg/dL 7.0 [3.0, 23.1] 6.1 [2.7, 19.0] 0.242
Data are presented as numbers (percentages).
∗Data are presented as the median [interquartile range].
†Chronic lung disease includes asthma, COPD, and structural lung diseases, such as bronchiectasis and interstitial lung disease.
ICU, intensive care unit; BMI, bodymass index; APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sequential Organ Failure Assessment.
4. Discussion
The majority of studies performed previously to investigate
sepsis focused on the role ofHDL orApoA-I and on the com-
parative analysis of mean values between survivor and non-
survivor groups or between sepsis and severe sepsis groups
[10, 22, 23]. In this study, we analyzed serum lipid levels
over time and the association of lipid levels with survival in
patients with sepsis.
Both HDL and Apo A-I were previously revealed
to be potential therapeutic agents for sepsis. Guo et al.
demonstrated that Apo A-I knockout mice were more sus-
ceptible to septic conditions and had a low capacity for LPS
neutralization or clearance, corticosterone generation, and
impaired leukocyte recruitment [24]. In addition, McDonald
et al. reported that recombinant HDL (rHDL) reduced the
severity of organ damage in rats preconditioned with E. coli.
However, in their study, rats pretreated with rHDL did not
display differences in hypotension events or serum levels of
TNF-𝛼 [25]. Furthermore, Chenaud et al. illustrated that low
serum levels ofApoA-I at ICUadmissionwere related to SIRS
exacerbation [10].
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Table 2: Analysis of survival by lipid profiles in ICU patients adjusted for age, sex, bodymass index, and Sequential Organ Failure Assessment
score.
Variables Median (IQR) Hazard ratio 95% CI 𝑝 value
Day 0
Cholesterol 95.0 [65.5, 132.0] 1.003 0.995 to 1.010 0.469
TG 92.0 [62.0, 137.3] 0.991 0.984 to 0.998 0.015
HDL 21.0 [11.3, 28.8] 1.018 0.991 to 1.045 0.192
LDL 40.0 [26.3, 68.3] 1.008 0.995 to 1.021 0.246
FFA 457.0 [256.3, 692.0] 0.999 0.998 to 1.000 0.124
Apo A-I 6.5 [2.8, 19.0] 1.000 0.945 to 1.025 0.986
Day 1
Cholesterol 88.0 [63.8, 116.3] 1.006 0.997 to 1.015 0.210
TG 93.0 [62.8, 145.3] 0.988 0.980 to 0.995 0.002
HDL 19.0 [10.0, 26.0] 1.024 0.996 to 1.052 0.091
LDL 37.0 [22.0, 64.0] 1.015 1.000 to 1.030 0.047
FFA 313.5 [166.0, 525.0] 0.999 0.997 to 1.000 0.146
Apo A-I 5.7 [2.7, 17.7] 1.004 0.978 to 1.030 0.780
Day 3
Cholesterol 88.0 [58.0, 113.5] 1.003 0.991 to 1.016 0.606
TG 90.0 [65.0, 130.0] 0.998 0.991 to 1.004 0.470
HDL 14.0 [8.0, 26.0] 1.034 0992 to 1.078 0.116
LDL 42.0 [23.8, 61.3] 1.013 0.994 to 1.032 0.189
FFA 301.0 [145.0, 394.5] 1.000 0.998 to 1.003 0.649
Apo A-I 5.3 [2.8, 17.6] 1.006 0.972 to 1.041 0.720
Day 7
Cholesterol 94.0 [76.0, 121.5] 0.994 0.981 to 1.008 0.393
TG 101.0 [73.0, 136.0] 0.999 0.987 to 1.009 0.728
HDL 19.5 [13.8, 26.0] 1.032 0.975 to 1.092 0.274
LDL 47.5 [30.5, 71.5] 0.986 0.968 to 1.005 0.156
FFA 301.0 [167.5, 403.0] 1.002 1.000 to 1.003 0.112
Apo A-I 8.5 [2.9, 18.7] 0.980 0.934 to 1.027 0.392
ICU, intensive care unit; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; FFA, free fatty acid; Apo A-I, apolipoprotein A-I; IQR,
interquartile range.
To date, only a few studies conducted survival analyses
according to serum lipid levels in patients with sepsis. In
our study, only TG levels on days 0 and 1 and LDL levels on
day 1 were associated with survival. Although other lipids
and lipoproteins illustrated significant differences over time
between the survivor and nonsurvivor groups, no significant
differences were found via survival analysis. This may be
explained by the complexity of ICU patients with sepsis.
In contrast to previous studies, which performed simple
comparisons between survivors and nonsurvivors, our study
reported that increased TG serum levels were significantly
associated with a decreased mortality rate [4]. Harris et al.
[26] and Barcia and Harris [6] explained this situation using
the lipoprotein binding capacity of endotoxin and host
defense mechanism to infection. The data suggested that
the mean TG level for the survivor group in our study was
similar to that in the low TG level group (survivor group) in
other studies [10, 23]. Furthermore, Chiarla et al. reported
that hypocholesterolemia, often paralleled by low TG
levels, is associated with a poor prognosis [27]. Thus, both
hypotriglyceridemia and hypertriglyceridemia could be
related with poor outcomes in patients with sepsis. The
absolute TG level may be important to some degree for the
prediction of mortality. Choi et al. reported that both high
and low TG levels were risk factors for poor early outcomes
after acute ischemic stroke [28]. In addition, it is possible that
racial and ethnic differences could have affected the results.
In general, Korean diets are low in fat.Therefore, the Koreans
usually have relatively low BMIs and low lipid blood levels
compared to the Europeans and Americans. These ethnic
features could explain the different results in our study in
comparison to previous studies. Therefore, extremely low
TG values may be associated with poor prognoses in ICU
patients with sepsis. Similarly, the HDL levels in our study
were lower than previously published values [10, 14, 22].
These relatively low HDL levels may explain why HDL
levels did not differ significantly between the survivor and
nonsurvivor groups. Recently, in two large, multicenter,
double-blind, randomized, placebo-controlled studies, sim-
vastatin and rosuvastatin did not improve clinical outcomes
in patients with ARDS or sepsis-associated ARDS (28- or
60-day inhospital mortality, ventilator-free days, or days
free of nonpulmonary organ failure) [11, 12]. These findings,
however, disagree with previous studies [29–31]. As reported
in these two large, randomized studies, our study reported
that in contrast to other studies, in particular, hypertri-
glyceridemia is related with poor prognoses [4, 32]. Further
large-scale studies are needed to investigate the therapeutic
role of HDL and the changes in HDL levels over time in
patients with sepsis.
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Figure 2: Time course of lipid levels in the survivor and nonsurvivor groups. Data for cholesterol (a), triglyceride (b), high-density lipoprotein
(c), low-density lipoprotein (d), free fatty acid (e), and apolipoprotein A-I (f) are shown. Data were collected on the day of admission and days
1, 3, and 7 after admission. The circle and bar represent the mean value and standard error of the mean, respectively. Significant differences
between the survivor and nonsurvivor groups are indicated by ∗.
We examined the correlation between the SOFA score and
lipid levels (Table 3). We found that TG levels did not corre-
late well with the SOFA score, unlike the other lipids. Thus,
we hypothesized that when TG levels are added to the SOFA
score, 28-day mortality predictions would be more precise
compared to using the SOFA score alone. The ROC curve
using TG level/SOFA score on day 0 exhibited a wider AUC
than the SOFA score alone,meaning that the 28-daymortality
prediction was more accurate. Li et al. reported that the com-
bination of soluble triggering receptor expression onmyeloid
cells-1 (sTREM-1), procalcitonin levels, and SOFA scores
could be a powerful predictor for patients with sepsis [33].
Previously, serial measurements of lactate and procalcitonin
were also helpful in the prediction of 28-daymortality [34]. In
our study, TG, as well as the aforementioned biomarkers, was
identified as a potential prognostic factor for patients with
sepsis.
There are some limitations to the current study. First,
we did not consider the nutritional status of the patients
before ICU admission, and we did not accurately calculate
caloric intake during the ICU care period. Weight history,
physical examination (e.g., skin and mucous membranes),
bowel function, and laboratory assessments, including pre-
albumin, retinol-binding protein, and transferrin levels, were
not investigated, which could be important for the results of
this study. However, a specialized nutrition team managed
the ICU patients with personalized nutrition assessments
using a standard protocol, and propofol was not used for
sedation in this period. Thus, the effect of nutrition differ-
ences between patients was acceptable. Second, inflammatory
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Table 3: Correlations between SequentialOrgan FailureAssessment
score and the serum concentrations of lipids in ICU patients with
sepsis.
Variable Correlation (rho) 𝑝 value
Day 0
Cholesterol −0.428 <0.001
TG −0.028 0.791
HDL −0.449 <0.001
LDL −0.418 <0.001
FFA 0.006 0.954
Apo A-I −0.279 0.007
Day 1
Cholesterol −0.454 <0.001
TG 0.066 0.545
HDL −0.470 <0.001
LDL −0.49 <0.001
FFA 0.249 0.021
Apo A-I −0.359 0.001
Day 3
Cholesterol −0.353 <0.001
TG 0.044 0.712
HDL −0.453 <0.001
LDL −0.466 <0.001
FFA −0.056 0.642
Apo A-I −0.414 <0.001
Day 7
Cholesterol −0.276 0.013
TG −0.158 0.231
HDL −0.398 0.002
LDL −0.312 0.017
FFA −0.156 0.248
Apo A-I −0.293 0.025
ICU, intensive care unit; TG, triglyceride; HDL, high-density lipoprotein;
LDL, low-density lipoprotein; FFA, free fatty acid; Apo A-I, apolipoprotein
A-I.
cytokines, such as TNF-𝛼, interleukin-1, and interleukin-6,
were not examined in our study. In septic conditions, it is well
known that these molecules affect lipid metabolism [35, 36].
These markers may have provided additional information on
the relationships between sepsis and lipid profiles. Third,
the duration of infection before sepsis was not calculated.
Once patients were exposed to LPS by infection, HDL levels
decreased, and thus the changes of serum lipid levels over
time in this study may have been affected by the duration of
time from infection to sepsis in each patient.
In conclusion, the changes in lipid profiles over time
differed significantly between the survivor and nonsurvivor
groups. Increased serum TG levels may be important in the
prognosis of patients with sepsis, as TG levels on days 0
and 1 were significantly associated with 28-day mortality. In
addition, the addition of TG to the SOFA score via ROC curve
analysis may improve the accuracy of mortality predictions.
Large-scale studies are required to confirm the role of lipid
and lipoprotein in the outcomes of ICU patients with sepsis.
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Figure 3: Receiver operator characteristic (ROC) curves of triglyc-
eride levels and Sequential Organ Failure Assessment (SOFA) scores
to predict mortality. On the day of admission, the area under curve
for triglyceride levels was 0.62 (sensitivity = 94.7%, specificity = 29.6,
and 𝑝 = 0.066), and that for the SOFA score was 0.63 (sensitivity =
21.2%, specificity = 96.9, and 𝑝 = 0.019). In addition, adjusting for
triglyceride levels with the SOFA score significantly improved the
predictive accuracy of 28-day mortality (AUC = 0.716, sensitivity =
71.1%, specificity = 66.7%, and 𝑝 < 0.001).
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